ArticleFrontiers in genetics2025
MSI expresso: a software for determining MSI status and detecting MSI-related transcription events from RNA sequencing data.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microsatellite instability (MSI) is becoming increasingly important in oncology as it has been reported across more than two dozen of solid cancer types. The MSI-high phenotype has long been used as a predictive and prognostic marker in colorectal cancer and has been recently approved by the FDA as a marker for immune checkpoint blockade therapy for solid cancers. Several bioinformatics tools have been developed to assess MSI status of a tumor sample using Next-Generation Sequencing (NGS) data mostly from whole genome, whole exome, and targeted gene sequencing data. While most tools available only infer the MSI status, none of them use RNA-sequencing (RNA-seq) data and provide per microsatellite expression and genotype results. We present MSI Expresso, a software which assesses the MSI status by testing the instability of a panel of 3'UTR microsatellites from RNA-seq data and also provides a detailed landscape of MSI-related events such as exon skipping, unstable coding and intronic microsatellites with a graphical output of the recurrent events. MSI Expresso's ability to detect the MSI status was assessed from RNA-seq data of 228 colon, 13 prostate and two endometrial cancer samples with known MSI status and achieved almost 100% concordant results. Thus, MSI Expresso is a new tool for MSI detection from RNA-sequencing data complementary to genomic and genetic approaches allowing to explore the consequence of MSI events on transcripts/transcriptome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.